Aberdeen Group
ABCL icon

Aberdeen Group’s AbCellera Biologics ABCL Stock Holding History

Aberdeen Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-278,528
Closed -$2.1M – 917
2023
Q1 		$2.1M Sell
278,528
-5,735
-2% -$52.1K 0.01% 716
2022
Q4 		$2.88M Buy
284,263
+8,831
+3% +$102K 0.01% 652
2022
Q3 		$2.72M Sell
275,432
-99,630
-27% -$1.09M 0.01% 652
2022
Q2 		$3.92M Sell
375,062
-35,390
-9% -$300K 0.01% 600
2022
Q1 		$4M Sell
410,452
-59,826
-13% -$566K 0.01% 632
2021
Q4 		$6.72M Buy
470,278
+44,400
+10% +$674K 0.01% 581
2021
Q3 		$8.45M Buy
425,878
+125,450
+42% +$2.22M 0.02% 530
2021
Q2 		$6.61M Buy
300,428
+120,300
+67% +$3.32M 0.01% 585
2021
Q1 		$6.18M Buy
+180,128
New +$7.18M 0.01% 596

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Aberdeen Group's ABCL Position: Q2 2023 in Review

Aberdeen Group sold out of AbCellera Biologics (ABCL) in Q2 2023, closing a stake of 278,528 shares — an estimated $2.1M sold.

Aberdeen Group first reported a position in ABCL in Q1 2021 and held it in 9 quarters. The position peaked at $8.45M in Q3 2021. 169 funds tracked by Wall St. Rank hold ABCL as of Q2 2023.

  • Aberdeen Group reported no remaining AbCellera Biologics position as of Q2 2023 after selling out during the quarter.
  • Aberdeen Group sold 278,528 AbCellera Biologics shares in Q2 2023, an estimated $2.1M.
  • Aberdeen Group first reported a position in AbCellera Biologics in Q1 2021 and held it in 9 quarters.
  • Aberdeen Group's AbCellera Biologics position peaked at $8.45M in Q3 2021.
  • 169 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2023.

Based on Aberdeen Group's 13F filing for Q2 2023, filed 4 Aug 2023.